메뉴 건너뛰기




Volumn 19, Issue 10, 2015, Pages 1277-1281

The quest for targeted therapy in fragile X syndrome

Author keywords

FMR1

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; RNA BINDING PROTEIN;

EID: 84941804598     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1079176     Document Type: Review
Times cited : (13)

References (13)
  • 1
    • 0025905795 scopus 로고
    • Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome
    • Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65 (5): 905-14
    • (1991) Cell , vol.65 , Issue.5 , pp. 905-914
    • Verkerk, A.J.1    Pieretti, M.2    Sutcliffe, J.S.3
  • 2
    • 0028246435 scopus 로고
    • Fmr1 knockout mice: A model to study fragile X mental retardation
    • Bakker CE, Verheij C, Willemsen R, et al. Fmr1 knockout mice: A model to study fragile X mental retardation. Cell 1994; 78: 23-33
    • (1994) Cell , vol.78 , pp. 23-33
    • Bakker, C.E.1    Verheij, C.2    Willemsen, R.3
  • 3
    • 0001966753 scopus 로고    scopus 로고
    • The physical and behavioural phenotype
    • Hagerman RJ, Hagerman P.,. editors The Johns Hopkins University Press; Baltimore:
    • Hagerman RJ. The physical and behavioural phenotype. In: Hagerman RJ, Hagerman P.,. editors. Fragile-X syndrome: diagnosis, treatment and research. The Johns Hopkins University Press; Baltimore: 2002. p. 3-109
    • (2002) Fragile-X Syndrome: Diagnosis, Treatment and Research , pp. 3-109
    • Hagerman, R.J.1
  • 4
    • 84886235508 scopus 로고    scopus 로고
    • Fragile X syndrome: From protein function to therapy
    • Bagni C, Oostra BA. Fragile X syndrome: From protein function to therapy. Am J Med Genet A 2013; 161A: 2809-21
    • (2013) Am J Med Genet A , vol.161 A , pp. 2809-2821
    • Bagni, C.1    Oostra, B.A.2
  • 5
    • 84899579632 scopus 로고    scopus 로고
    • Fragile X syndrome neurobiology translates into rational therapy
    • Braat S, Kooy RF. Fragile X syndrome neurobiology translates into rational therapy. Drug Discov Today 2014; 19: 510-19
    • (2014) Drug Discov Today , vol.19 , pp. 510-519
    • Braat, S.1    Kooy, R.F.2
  • 6
    • 84921811954 scopus 로고    scopus 로고
    • Independent role for presynaptic FMRP revealed by an FMR1 missense mutation associated with intellectual disability and seizures
    • Myrick LK, Deng P, Hashimoto H, et al. Independent role for presynaptic FMRP revealed by an FMR1 missense mutation associated with intellectual disability and seizures. Proc Natl Acad Sci USA 2015; 112: 949-56
    • (2015) Proc Natl Acad Sci USA , vol.112 , pp. 949-956
    • Myrick, L.K.1    Deng, P.2    Hashimoto, H.3
  • 7
    • 33750962399 scopus 로고    scopus 로고
    • Effect of CX516, an AMPA-modulating com-pound, on cognition and behavior in fragile X syndrome: A controlled trial
    • Berry-Kravis E, Krause SE, Block SS, et al. Effect of CX516, an AMPA-modulating com-pound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 2006; 16 (5): 525-40
    • (2006) J Child Adolesc Psychopharmacol , vol.16 , Issue.5 , pp. 525-540
    • Berry-Kravis, E.1    Krause, S.E.2    Block, S.S.3
  • 8
    • 78650937072 scopus 로고    scopus 로고
    • Epigenetic modification of the FMR1 gene in fragile x syndrome is associated with differential response to the mGluR5 Antagonist AFQ056
    • Jacquemont S, Curie A, des Portes V, et al. Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056. Sci Transl Med 2011; 3 (64): 64ra1
    • (2011) Sci Transl Med , vol.3 , Issue.64 , pp. 64ra1
    • Jacquemont, S.1    Curie, A.2    Des Portes, V.3    Al, E.4
  • 9
    • 77957678816 scopus 로고    scopus 로고
    • Open-label add-on treatment trial of minocycline in fragile X syndrome
    • Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010; 10 (1): 91
    • (2010) BMC Neurol , vol.10 , Issue.1 , pp. 91
    • Paribello, C.1    Tao, L.2    Folino, A.3
  • 10
    • 84876358587 scopus 로고    scopus 로고
    • A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome
    • Leigh MJ, Nguyen DV, Mu Y, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr 2013; 34 (3): 147-55
    • (2013) J Dev Behav Pediatr , vol.34 , Issue.3 , pp. 147-155
    • Leigh, M.J.1    Nguyen, D.V.2    Mu, Y.3
  • 11
    • 79960779323 scopus 로고    scopus 로고
    • FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism
    • Darnell JC, Van Driesche SJ, Zhang C, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011; 146 (2): 247-61
    • (2011) Cell , vol.146 , Issue.2 , pp. 247-261
    • Darnell, J.C.1    Van Driesche, S.J.2    Zhang, C.3
  • 12
    • 84886298245 scopus 로고    scopus 로고
    • Epigenetics, fragile X syndrome and transcriptional therapy
    • Tabolacci E, Chiurazzi P. Epigenetics, fragile X syndrome and transcriptional therapy. Am J Med Genet A 2013; 161A (11): 2797-808
    • (2013) Am J Med Genet A , vol.161 A , Issue.11 , pp. 2797-2808
    • Tabolacci, E.1    Chiurazzi, P.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.